Industry research

What predicts a close in healthcare and life sciences.

The short answer

A clinical champion plus a compliance path. Both, or neither counts.

How Kaypo answers this on your pipeline

30 minutes with the founder

See how Kaypo helps your pipeline

Thirty minutes on your pipeline or the example one. Pick a time and it is booked.

The argument

Health systems have the largest buying committees in B2B and the longest silences. Conversation intelligence is weighted high because a named clinical champion is the single best predictor here, and champions reveal themselves on calls rather than on websites. Buying process is close behind: a business associate agreement, a security assessment, or a clinical review is real progress. Long gaps are structural, not fatal, so the going quiet signature is reduced. The committee signature is amplified because a second and third stakeholder appearing is the actual mechanism by which these deals advance, and a deal that never adds a second name almost never closes.

The weights

Published, because a score you cannot audit is a score nobody trusts.

76% of the score comes from what the company does, 24% from what named people do. Within each side, these are the shares.

Company signals

Buying process
40%
Conversation intelligence
28%
Pipeline history
18%
Third party intent
14%
Anonymous site visits
0%

Person signals

Meeting behavior
34%
Site behavior
24%
Responsiveness
24%
Marketing engagement
18%

See it against a real pipeline.

The demo loads with these weights. Move them and watch the deals reorder.

Past the score.

The same evidence finds accounts: past champions who moved, companies hiring the way your wins did, and companies that look like your wins, with lead routing and agents on top. Every list is checked against your own won and lost deals, so what counts in your industry is what counted for you.

Kaypo for mid-market teamsJob postings that come before a deal

All industries